Pluri Inc. Reports Revenue Growth to $938,000 Amid Ongoing Net Loss

Pluri Inc. reported its financial results for the nine months ending March 31, 2025, revealing a significant increase in revenue compared to the same period last year. The company generated $938,000 in revenue, up from $230,000 in the prior year, with the most recent quarter showing revenues of $427,000 compared to $71,000 in the same quarter of 2024. This growth is attributed primarily to the launch of new business verticals, particularly in the Contract Development and Manufacturing Organization (CDMO) sector, and increased collaboration in the agricultural technology field.

Despite the revenue growth, Pluri Inc. continues to face challenges, reporting a net loss of $15.5 million for the nine-month period, slightly down from a loss of $15.48 million in the previous year. The net loss per share attributed to shareholders was $2.56, an improvement from $2.92 in the prior year. The company’s accumulated deficit has reached approximately $435.5 million, reflecting ongoing operational losses since its inception. The total shareholders' equity stood at $483,000, with a working capital surplus of $21.75 million as of March 31, 2025.

Operationally, Pluri Inc. has made strategic moves, including the acquisition of approximately 71% of Kokomodo Ltd., an Israeli agtech company, for $4.5 million in common shares. This acquisition, completed on April 28, 2025, is expected to enhance Pluri's capabilities in cultivated cacao production. Additionally, the company has launched its PluriCDMO™ division, which is already generating revenue from clients in the biotechnology sector. The company also reported a significant increase in its employee headcount, reflecting its expansion efforts.

In terms of financial management, Pluri Inc. has been actively seeking additional funding sources to support its operations and R&D activities. The company has entered into various securities purchase agreements, raising approximately $10 million through the issuance of common shares and warrants. Furthermore, Pluri is in discussions with the European Investment Bank regarding the restructuring of a €20 million loan, which is due in June 2026. The company anticipates that its current resources will be sufficient to meet its obligations for at least the next twelve months, although it acknowledges the need for further funding to support long-term growth.

Looking ahead, Pluri Inc. remains focused on its core areas of regenerative medicine, food technology, and agricultural technology. The company plans to continue leveraging its advanced cell-based technology platform to drive innovation and expand its market presence. However, it cautions that significant revenue generation from product sales is not expected in the near term, and it will rely on CDMO services and collaborations to sustain its operations. The company is also closely monitoring market conditions and potential impacts from geopolitical factors, particularly in the context of its operations in Israel.